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Background: A. xylosoxidans (Ax) is capable of persistent infection of the respira-
tory tract of Cystic Fibrosis patients although its contribution to pulmonary decline
in this population is not clear.
Aim: To evaluate pathogenic role of Ax studying lung function and nutritional
status in CF patients with chronic Ax infection.
Methods: Data (FEV1, FVC, BMI, sputum and number of IV therapy) of 20
CF patients in follow-up at our centre were studied retrospectively at the time of
establishment of infection (T0), one year before (T-1) and one year after (T+1) and
were then compared. Statistical analysis was performed by Student’s T test. Mean
age of the 20 (13 females) patients was 14.5 (range 6.2−23.3) at T0.
Results: Lung function showed a slight decrease in the year before the acquisition
of Ax both in FVC (91.2±20.4 vs 86.1±12.6%/predicted p = 0.22) and FEV1
(84.4±20.5 vs 79.1±16.3 %/predicted p = 0.09), without reaching statistical sig-
niﬁcance. Respiratory data showed no deterioration in the year after infection: FVC
(88.4±18.1 vs 86.1±12.6%/predicted p = 0.47) and FEV1 (82.9±23.2 vs 79.1±16.3
%/predicted p = 0.26). However, the number of respiratory exacerbations was much
higher in the year after colonisation as demonstrated by the i.v. treatment mean
days per patient (12.1±15.5 vs 3.1±6.5, p = 0.03).
Nutritional status remained unchanged during the study period as demonstrated by
BMI of T-1 vs T0 (18.1±2.9 vs 18.1±3.1 p = 0.77) and T0 vs T+1 (18.1±3.1 vs
18.7±2.9 p = 0.07).
Conclusion: The pathogenic role of chronic infection by Ax seems to be relevant
in terms of therapeutic burden for patients in the short-term. A key factor would
be monitoring the evolution of the patients chronically infected by Ax.
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Oxidative status has a role in the progressive lung damage in CF. Glutathione is
an important defence from pro-antioxidant agents and it is reduced in CF. Cysteine
is the amino acid that gives to glutathione antioxidant status. The objective of this
study is to reduce the oxidative status in CF with oral addition of whey protein
isolate with high content of cysteine (PROther). We recruit CF patients older than
6 years, with a FEV1<70%, with a BMI <21 kg/m2 in adults and with a weight
<25º centile in children. Oxidative status is estimated on a blood sample with
d-ROMs test and BAP test that can measure oxidative stress and antioxidant status
respectively. The study has started in May 2007 and will last for 12 months. Patients
will be checked every three months. We have planed the enrolment of 50 patients
at least. During the follow-up at every examination we will control oxidative status,
clinical conditions (nutritional status, growth, lung function), compliance to the
administration of PROther, alimentary intake and Quality of life. We recruited
32 patients still now. All cases show a pathological condition of oxidative status.
Oxidative stress is increased in all patients and in 52% of cases is very serious.
Antioxidant status is normal in 46% of cases and 14% show a high deﬁciency. Four
patients deserted the study for a bad compliance to the administration of PROther
not related to the product. In 6 patients we have done the ﬁrst control after three
months from the recruitment. All these cases show an improved oxidative status.
Oxidative stress has become normal in one patient. Antioxidant status has become
normal in 4 cases. All 6 patients report subjective clinical improvement. On the base
of the clinical parameters, respiratory and nutritional conditions are stable in 4 cases
and improved in 2. The quality of life test is better in all patients. Collected data
conﬁrm a high level of oxidative status in CF patients. Oral addition of whey protein
isolate with high content of cysteine seems efﬁcacious to improve the oxidative
status. Oxidative status improvement could correlate to a clinical improvement.
These observations coming from preliminary data must be conﬁrmed. We think
useful to continue the valuation of the efﬁcacy of oral addition of PROther and we
consider antioxidant therapy potentially important in CF.
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The hallmarks of cystic ﬁbrosis (CF) lung disease are bacterial infections by oppor-
tunistic pathogens and chronic inﬂammation, characterized by polymorphonucleate
neutrophils predominance, progressing to obstructive lung disease and bronchiec-
stasis.
High levels of sputum tumor necrosis factor (TNF)-a and interleukin (IL)-8 and
serum IL-6 have been found in CF patients. The aim of this study was to analyze
the major cytokines such as IL-1a, IL-1b, IL-2, IL-4, IL-6, IL-10, interferon (IFN)-
g, the chemokines IL-8, monocyte chemoattractant protein-1 (MCP-1) and the
growth factors epidermal growth factor (EGF) and vascular endothelial growth
factor (VEGF) before and after antibiotic therapy in serum, sputum and exhalate in
order to clarify the process involved in the CF inﬂammation and to evaluate which
is the best matrix which can deﬁne this process.
We considered 10 CF patients (median age 19.5± 4, 6 M, 4 F) who were admitted at
the CF Center of the University of Milan for i.v. antibiotic therapy during acute res-
piratory exacerbation. Before and after treatment all patients underwent routine lab-
oratory determinations, sputum culture and standard spirometry. Serum, sputum and
exhalate interleukins, chemokines and growth factors were analyzed simultaneously
by means of the Evidence® biochip array (Randox) on semiautomated instrument.
Results at admission and the percentage of signiﬁcant changes after six months are
reported in the table. After treatment, chemokines and growth factors decreased
in a different manner for the considered matrix, only VEGF seemed to be always
signiﬁcantly decreased. No signiﬁcant change was found for IFN-g, IL-6 and IL-4.
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Serum Mean 5.8 4.1 34.7 378 1.5 187 3.41 8.06 0.68 2.28 367 135
SD 4.6 3.5 69.0 935 1.4 128 3.59 5.83 0.74 2.82 286 107
change (%) −26 −41 −34 −28 −56
Sputum Mean 6.9 12.2 10.5 21852 6.2 2297 1.66 153 102 1344 66 493
SD 11.0 6.1 12.4 15540 10.9 1412 5.71 239 123 1103 72 548
change (%) −78 −41 −56 73 −10
Exhalate Mean 2.1 4.6 0.2 0.4 0.6 12.2 3.43 1.79 0.43 1.24 2.47 0.60
SD 4.0 4.9 0.3 0.2 1.1 32.2 9.74 3.93 0.22 2.11 3.94 0.25
change (%) −17 −52 −75 −12 −59
In conclusion, antibiotic therapy in CF patients could be monitored by cytokine
proﬁles in sputum and serum, while exalate levels are too low to be useful. VEGF,
a growth factor involved in tissue remodeling, needs further studies.
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Diabetes in Cystic Fibrosis (CFRD) is increasingly common with advancing age
because of a combination of insulin resistance and insulin secretory defects. Many
patients are normoglycemic or even hypoglycemic after overnight fast, and there
are repeated changes of glucose tolerance status from normal to diabetes and vice-
versa, for many years and for unclear reasons. These features render difﬁcult the
prediction of CFRD development.
This study aimed to detect predictive factors of CFRD development in patients
routinely undergoing yearly Oral Glucose Tolerance Test (OGTT) evaluations.
Starting from 2002, all patients followed at the CF Center in Milan aged >10 years
and without established CFRD undergo OGTT yearly. Among those who received
their ﬁrst OGTT between 2002 and 2004, 14 had developed deﬁnitive diabetes
by April 2007. Each of them was matched with patients of same sex and age,
who underwent an OGTT in the same month and year but did not develop CFRD
(n = 20). Logistic regression, controlled for age, sex and follow-up time, was used
to identify CFRD predictors among factors including glucose, insulin and c-peptide
concentrations and area under the curve (AUC) during OGTT, insulin sensitivity
indexes (HOMA and QUICKI).
In the group that developed CFRD, baseline glucose concentration was increased
(92±6 vs 72±3mg/dl, mean±SEM, p = 0.034) whereas insulin and c-peptide
concentrations were similar (5.4±0.61 vs 7.8±1.4 mU/ml, and 1.4±0.1 vs 1.4±0.2
ng/ml). Glucose (p = 0.010) and insulin AUCs (p = 0.030) were the most important
